Olivia Newton-John Cancer Wellness and Research Centre

OrgUnit's Researchers
(Persons)

Results 1-5 of 45 (Search time: 0.002 seconds).

FullnameTranslated NameEmail
Berlangieri, AlexandraAlexandra.BERLANGIERI@austin.org.au
Berlangieri, Salvatore USam.Berlangieri@austin.org.au
Berry, ColleenColleen.BERRY@austin.org.au
Brown, KerrynKez.Brown@austin.org.au
Burgess, Adele NAdele.BURGESS@austin.org.au

OrgUnit's Researchers publications
(Dept/Workgroup Publication)

Results 701-720 of 927 (Search time: 0.011 seconds).

Publication YearTitleAuthor(s)
7017-Nov-2022Randomized Controlled Trial of a Smartphone Based Intervention to Enhance Six Minute Walk Distance During Breast Cancer Treatment: the SMART-BREAST Trial.Murphy, Alexandra C ; Farouque, Omar ; Koshy, Anoop N ; Yeo, Belinda ; Dick, Ron; Nadurata, Voltaire; Roccisano, Laura; Reid, Christopher; Yudi, Matias B 
70223-May-2011Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.Mitchell, Paul L R ; Broad, Adam; Rosenthal, Mark A; Galettis, Peter; Abraham, Rick; Burns, Ivon; Clarke, Stephen; Milner, Alvin; Diiulio, Juliana; Links, Matthew
7031-Nov-2021A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).Mitchell, Paul L R ; O'Byrne, K J; Brown, C; Jurkovic, H; Karapetis, C S; Kok, P S; Lao, L; Le, H V; Pavlakis, N; Ab Rahman, A S; Subramaniam, S; Walker, M; Yip, S; Stockler, M R; Siva, S
70411-Jun-2014Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Van Cutsem, Eric; Eng, Cathy; Nowara, Elzbieta; Swieboda-Sadlej, Anna; Tebbutt, Niall C ; Mitchell, Edith; Davidenko, Irina; Stephenson, Joe; Elez, Elena; Prenen, Hans; Deng, Hongjie; Tang, Rui; McCaffery, Ian; Oliner, Kelly S; Chen, Lisa; Gansert, Jennifer; Loh, Elwyn; Smethurst, Dominic; Tabernero, Josep
705Sep-2016A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junctionShah, Manish A; Cho, Jae-Yong; Tan, Iain B; Tebbutt, Niall C ; Yen, Chia-Jui; Kang, Alice; Shames, David S; Bu, Lilian; Kang, Yoon-Koo
706Apr-2017Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.García-Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall C ; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A; Funke, Roel; Anderson, Maria; McCall, Bruce; Stroh, Mark; Wakshull, Eric; Hegde, Priti; Ye, Weilan; Chen, Daniel; Chang, Ilsung; Rhee, Ina; Hurwitz, Herbert
707May-2022A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.Capdevila, Jaume; Klochikhin, Arkadiy; Leboulleux, Sophie; Isaev, Pavel; Badiu, Corin; Robinson, Bruce; Hughes, Brett G M; Keam, Bhumsuk; Parnis, Francis; Elisei, Rossella; Gajate, Pablo; Gan, Hui K ; Kapiteijn, Ellen; Locati, Laura; Mangeshkar, Milan; Faoro, Leonardo; Krajewska, Jolanta; Jarzab, Barbara
70826-May-2022Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma.Shah, Manish A; Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Tebbutt, Niall C ; Metges, Jean-Phillippe; Muro, Kei; Lee, Keun-Wook; Shen, Lin; Tjulandin, Sergei; Hays, John L; Starling, Naureen; Xu, Rui-Hua; Sturtz, Keren; Fontaine, Marilyn; Oh, Cindy; Brooks, Emily; Xu, Bo; Li, Wei; Li, Chiang J; Borodyansky, Laura; Van Cutsem, Eric
70914-Jul-2022Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Shah, Manish A; Shitara, Kohei; Lordick, Florian; Bang, Yung-Jue; Tebbutt, Niall C ; Metges, Jean-Phillippe; Muro, Kei; Lee, Keun-Wook; Shen, Lin; Tjulandin, Sergei; Hays, John L; Starling, Naureen; Xu, Rui-Hua; Sturtz, Keren; Fontaine, Marilyn; Oh, Cindy; Brooks, Emily M; Xu, Bo; Li, Wei; Li, Chiang J; Borodyansky, Laura; Van Cutsem, Eric
71022-Feb-2021Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK.Lau, David K ; Luk, Ian Y; Jenkins, Laura J; Martin, Andrew; Williams, David S ; Schoffer, Kael L; Chionh, Fiona; Buchert, Michael; Sjoquist, Katrin; Boussioutas, Alex; Hayes, Sarah A; Ernst, Matthias ; Weickhardt, Andrew J ; Pavlakis, Nick; Tebbutt, Niall C ; Mariadason, John M 
711Aug-2023Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy.Wang, Yang; Mathai, Jared; Alamgeer, Muhammad; Parakh, Sagun ; Paul, Eldho; Mitchell, Paul L R ; Arulananda, Surein
712Aug-2023Real-world data on patterns and outcomes of radiation therapy for brain metastases in a population-based cohort of lung cancer patients in Victoria.Kang, Therese Min Jung; Ratnayake, Gishan; Wada, Morikatsu ; Phillips, Claire; Ruben, Jeremy; Senthi, Sashendra; Foroudi, Farshad ; Millar, Jeremy; Ong, Wee Loon 
713Dec-2020Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer.Conduit, C; de Boer, R H; Lok, S; Gibbs, P; Malik, L; Loh, Zoe ; Yeo, Belinda ; Greenberg, S; Devitt, B; Lombard, J; Nottage, M; Collins, I; Torres, J; Nolan, M; Nott, L
71414-Jul-2022Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.Tung, Iris; Moldovan, Cristina; Wong, Vanessa ; De Boer, Richard; Yeo, Belinda ; Malik, Laeeq; Greenberg, Sally; Anton, Angelyn; Nott, Louise; Barnett, Frances; Collins, Ian M; Lombard, Janine; Nottage, Michelle; Sahu, Arvind; Torres, Javier; Gibbs, Peter; Lok, Sheau Wen
71526-Apr-2021The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.Rees, Matthew J ; Wu, Simon; Mokoonlall, Mridula; Dix, Caroline H K; Bryant, Christian E; D'Rozario, James; Schwarer, Anthony P ; Grigg, Andrew P ; Tiong, Ing S 
716May-2022Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.Nguyen, Phillip C; Donati, Vanessa; Vassili, Catherine; Grigg, Andrew P ; Tiong, Ing S 
71715-Nov-2021Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists.Xing, Daniel T ; Khor, Richard ; Gan, Hui K ; Wada, Morikatsu ; Ermongkonchai, Tai; Ng, Sweet Ping 
7188-Mar-2018Receptor Occupancy Imaging Studies in Oncology Drug Development.Burvenich, Ingrid J G; Parakh, Sagun ; Parslow, Adam C; Lee, Sze Ting ; Gan, Hui K ; Scott, Andrew M 
719Jul-2022Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.Tam, Constantine S; Gregory, Gareth P; Ku, Matthew; Fleming, Shaun; Handunnetti, Sasanka M; Lee, Denise; Walker, Patricia; Perkins, Andrew; Lew, Thomas E; Sirdesai, Shreerang; Chua, Chong Chyn ; Gilbertson, Michael; Lasica, Masa; Anderson, Mary Ann; Renwick, William; Grigg, Andrew P ; Patil, Sush; Opat, Stephen; Friebe, Adam; Cooke, Rachel; De Boer, Jasper; Spencer, Andrew; Ritchie, David; Agarwal, Rishu ; Blombery, Piers
7202019Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.Forsyth, Cecily J; Chan, Wai-Hoong; Grigg, Andrew P ; Cook, Nathalie C; Lane, Steven W; Burbury, Kate L; Perkins, Andrew C; Ross, David M